West Pharmaceutical Services Inc. (NYSE:WST) reached a new 52-week high on Friday . The stock traded as high as $77.80 and last traded at $77.20, with a volume of 103,411 shares traded. The stock had previously closed at $76.30.

Several equities research analysts have weighed in on the company. Jefferies Group reiterated a “hold” rating and issued a $67.00 price objective on shares of West Pharmaceutical Services in a report on Thursday, June 9th. Zacks Investment Research upgraded West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $81.00 price objective for the company in a report on Wednesday, April 20th. Wells Fargo & Co. assumed coverage on West Pharmaceutical Services in a report on Tuesday, March 22nd. They issued an “outperform” rating for the company. Finally, Janney Montgomery Scott reiterated a “buy” rating and issued a $90.00 price objective (up previously from $69.00) on shares of West Pharmaceutical Services in a report on Friday, May 13th.

The firm has a 50 day moving average of $74.86 and a 200-day moving average of $66.59. The firm has a market capitalization of $5.65 billion and a price-to-earnings ratio of 67.14.

West Pharmaceutical Services (NYSE:WST) last posted its earnings results on Thursday, April 28th. The company reported $0.53 EPS for the quarter, topping analysts’ consensus estimates of $0.51 by $0.02. During the same quarter in the prior year, the firm posted $0.45 earnings per share. The firm earned $362.10 million during the quarter, compared to analysts’ expectations of $355.86 million. West Pharmaceutical Services’s quarterly revenue was up 7.8% on a year-over-year basis. On average, equities analysts forecast that West Pharmaceutical Services Inc. will post $2.21 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, August 3rd. Investors of record on Wednesday, July 20th will be given a $0.12 dividend. The ex-dividend date is Monday, July 18th. This represents a $0.48 dividend on an annualized basis and a dividend yield of 0.63%.

In related news, VP Daniel Malone sold 3,950 shares of the business’s stock in a transaction dated Thursday, June 2nd. The stock was sold at an average price of $74.95, for a total value of $296,052.50. Following the sale, the vice president now directly owns 30,666 shares in the company, valued at $2,298,416.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Thomas W. Hofmann sold 2,466 shares of the business’s stock in a transaction dated Wednesday, May 25th. The stock was sold at an average price of $73.57, for a total value of $181,423.62. Following the completion of the sale, the director now owns 34,506 shares in the company, valued at $2,538,606.42. The disclosure for this sale can be found here.

Other large investors have recently bought and sold shares of the company. GSA Capital Partners LLP increased its stake in West Pharmaceutical Services by 17.9% in the fourth quarter. GSA Capital Partners LLP now owns 17,134 shares of the company’s stock worth $1,032,000 after buying an additional 2,601 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its stake in West Pharmaceutical Services by 0.5% in the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 20,900 shares of the company’s stock worth $1,259,000 after buying an additional 113 shares in the last quarter. Whittier Trust Co. increased its stake in West Pharmaceutical Services by 93.1% in the fourth quarter. Whittier Trust Co. now owns 21,387 shares of the company’s stock worth $1,288,000 after buying an additional 10,312 shares in the last quarter. BHF Kleinwort Benson Group S.A. increased its stake in West Pharmaceutical Services by 64.5% in the fourth quarter. BHF Kleinwort Benson Group S.A. now owns 21,524 shares of the company’s stock worth $1,296,000 after buying an additional 8,438 shares in the last quarter. Finally, ProShare Advisors LLC increased its stake in West Pharmaceutical Services by 26.9% in the fourth quarter. ProShare Advisors LLC now owns 23,036 shares of the company’s stock worth $1,387,000 after buying an additional 4,879 shares in the last quarter.

West Pharmaceutical Services, Inc is a manufacturer of components and systems for the packaging and delivery of injectable drugs, as well as delivery system components for the pharmaceutical, healthcare and consumer products industries. The Company’s products include stoppers and seals for vials, prefillable syringe components and systems, components for intravenous and blood collection systems, safety and administration systems, advanced injection systems, and contract design and manufacturing services.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.